Vinge advises Calliditas Therapeutics in connection with its capital raising and listing on The Nasdaq Global Select Market in United States.
The trading on The Nasdaq Global Select Market in United States began on 5 June 2020. The total value of the global offering amounts to approximately USD 103.5 million, assuming that the over allotment option is fully exercised.
Calliditas is a specialty pharmaceutical company, focused on the development and commercialization of the product candidate Nefecon, intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.
Vinge’s team consisted of Dain Hård Nevonen, Sofie Bjärtun, Nils Fredrik Dehlin, Hampus Olsson and Julia Hirschberg.
